Dishman Carbogen Amcis Ltd Hits Intraday High with 7.31% Surge on 3 Feb 2026

Intraday Trading Highlights

The stock opened with a notable gap-up, rising 4.46% from its previous close, signalling strong buying momentum from the outset. Throughout the trading session, Dishman Carbogen Amcis Ltd maintained upward pressure, ultimately reaching an intraday peak of Rs 233.5, representing an 8.4% increase from the prior day’s closing price. This intraday high marks a continuation of the stock’s positive momentum, as it has now recorded gains for two consecutive sessions, accumulating a 5.9% return over this period.

In comparison, the Pharmaceuticals & Biotechnology sector, to which the company belongs, gained 2.8% on the day, while the Sensex index closed with a more modest advance of 2.49%. Dishman Carbogen Amcis Ltd’s outperformance by 2.67% relative to its sector underscores its strong relative strength in today’s market environment.

Technical Positioning and Moving Averages

From a technical standpoint, the stock’s price currently trades above its 5-day moving average, reflecting short-term bullishness. However, it remains below its 20-day, 50-day, 100-day, and 200-day moving averages, indicating that while immediate momentum is positive, the stock has yet to break through longer-term resistance levels. This mixed technical picture suggests that the recent gains are part of a short-term rally within a broader consolidation phase.

Market Context and Sector Activity

The broader market displayed mixed signals on the day. The Sensex opened strongly, surging 3,656.74 points higher, but subsequently lost momentum, retreating by 1,610.24 points to close at 83,712.96, down 2.51% from its intraday peak. Despite this volatility, the Sensex remains close to its 52-week high of 86,159.02, just 2.92% away. The index is trading below its 50-day moving average, though the 50-day average itself is positioned above the 200-day moving average, a configuration often interpreted as a positive medium-term trend.

Within this environment, mega-cap stocks led the market’s gains, while the Pharmaceuticals & Biotechnology sector showed resilience with a 2.8% rise. Dishman Carbogen Amcis Ltd’s performance outpaced both the sector and the broader index, highlighting its distinct intraday strength.

Performance Trends Over Various Timeframes

Examining the stock’s performance over multiple periods reveals a mixed trajectory. Over the past day, the 7.31% gain significantly outpaces the Sensex’s 2.49% rise. Over the last week, Dishman Carbogen Amcis Ltd has surged 13.92%, well above the Sensex’s 2.26% increase, indicating strong short-term momentum.

However, the stock’s performance over longer durations has been less favourable. It has declined 9.35% over the past month and 20.74% over three months, compared to the Sensex’s more modest declines of 2.40% and 0.33% respectively. Year-to-date, the stock is down 6.76%, underperforming the Sensex’s 1.78% fall. Over one year, the stock has posted a modest 1.54% gain, lagging the Sensex’s 8.44% advance.

On a more extended horizon, the stock has delivered substantial returns, rising 178.16% over three years and 82.58% over five years, outperforming the Sensex’s respective gains of 37.58% and 66.55%. The 10-year performance is flat at 0.00%, compared to the Sensex’s 245.55% growth, reflecting a complex long-term pattern.

Mojo Score and Rating Update

Dishman Carbogen Amcis Ltd currently holds a Mojo Score of 32.0, with a Mojo Grade of Sell, reflecting a downgrade from its previous Hold rating as of 12 Jan 2026. The Market Cap Grade stands at 3, indicating a mid-tier market capitalisation within its sector. These ratings provide a snapshot of the stock’s current standing within the Pharmaceuticals & Biotechnology industry, which continues to experience varied performance across its constituents.

Summary of Today’s Trading Action

Dishman Carbogen Amcis Ltd’s strong intraday performance on 3 Feb 2026 was characterised by a significant gap-up opening, sustained buying interest, and a peak price of Rs 233.5, representing an 8.4% rise from the previous close. The stock’s gains outpaced both the Pharmaceuticals & Biotechnology sector and the broader Sensex index, highlighting its relative strength amid a volatile market backdrop.

While the stock remains below several longer-term moving averages, its current position above the 5-day average suggests short-term bullish momentum. The recent two-day consecutive gains and outperformance relative to the sector reinforce this trend. However, the broader market’s mixed performance and the stock’s varied longer-term returns indicate a nuanced trading environment.

Investors and market participants will likely continue to monitor the stock’s price action and technical indicators closely in the coming sessions to assess whether this intraday strength can be sustained or if it represents a short-lived rally within a broader consolidation phase.

Unlock special upgrade rates for a limited period. Start Saving Now →